Intravenous tissue-type plasminogen activator for treatment of acute stroke: The standard treatment with alteplase to reverse stroke (STARS) study

Gregory W. Albers, Vernice E. Bates, Wayne Clark, Rodney Bell, Piero Verro, Scott A. Hamilton

Research output: Contribution to journalArticle

595 Citations (Scopus)

Abstract

Context: Tissue-type plasminogen activator (tPA) is the only therapy for acute ischemic stroke approved by the Food and Drug Administration. Objective: To assess the safety profile and to document clinical outcomes and adverse events in patients treated with intravenous tPA for acute stroke in clinical practice. Design and Setting: Prospective, multicenter study of consecutive patients enrolled between February 1997 and December 1998 at 57 medical centers in the United States (24 academic and 33 community). Intervention: Intravenous tPA (recombinant alteplase). Patients: Three hundred eighty-nine patients with a mean age of 69 years (range, 28-100 years); 55% were men. Main Outcome Measures: Time intervals between stroke symptom onset, hospital arrival, and treatment with tPA; pretreatment computed tomographic scan results, intracerebral hemorrhage, and major systemic bleeding. The modified Rankin Scale score was used to assess clinical outcomes at 30 days. Results: Median time from stroke onset to treatment was 2 hours 44 minutes, and the median baseline National Institutes of Health Stroke Scale score was 13. The 30-day mortality rate was 13%. At 30 days after treatment, 35% of patients had very favorable outcomes (modified Rankin score, 0-1) and 43% were functionally independent (modified Rankin score, 0-2). Thirteen patients (3.3%) experienced symptomatic intracerebral hemorrhage, including 7 who died. Twenty-eight patients (8.2%) had asymptomatic intracerebral hemorrhage within 3 days of treatment with tPA. Protocol violations were reported for 127 patients (32.6%), and included treatment with tPA more than 3 hours after symptom onset in 13.4%, treatment with anticoagulants within 24 hours of tPA administration in 9.3%, and tPA administration despite systolic blood pressure exceeding 185 mm Hg in 6.7%. A multivariate analysis found predictors of favorable outcome to be a less severe baseline National Institutes of Health Stroke Scale score, absence of specific abnormalities (effacement or hypodensity of >33% of the middle cerebral artery territory or a hyperdense middle cerebral artery) on the baseline computed tomographic scan, an age of 85 years or younger, and a lower mean arterial pressure at baseline. Conclusions: This study, conducted at multiple institutions throughout the United States, suggests that favorable clinical outcomes and low rates of symptomatic intracerebral hemorrhage can be achieved using tPA for stroke treatment.

Original languageEnglish (US)
Pages (from-to)1145-1150
Number of pages6
JournalJournal of the American Medical Association
Volume283
Issue number9
StatePublished - Mar 1 2000
Externally publishedYes

Fingerprint

Plasminogen Activators
Tissue Plasminogen Activator
Stroke
Cerebral Hemorrhage
Middle Cerebral Artery
National Institutes of Health (U.S.)
Therapeutics
Blood Pressure
United States Food and Drug Administration
Anticoagulants
Multicenter Studies
Arterial Pressure
Multivariate Analysis
Outcome Assessment (Health Care)
Prospective Studies
Hemorrhage
Safety
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Intravenous tissue-type plasminogen activator for treatment of acute stroke : The standard treatment with alteplase to reverse stroke (STARS) study. / Albers, Gregory W.; Bates, Vernice E.; Clark, Wayne; Bell, Rodney; Verro, Piero; Hamilton, Scott A.

In: Journal of the American Medical Association, Vol. 283, No. 9, 01.03.2000, p. 1145-1150.

Research output: Contribution to journalArticle

Albers, Gregory W. ; Bates, Vernice E. ; Clark, Wayne ; Bell, Rodney ; Verro, Piero ; Hamilton, Scott A. / Intravenous tissue-type plasminogen activator for treatment of acute stroke : The standard treatment with alteplase to reverse stroke (STARS) study. In: Journal of the American Medical Association. 2000 ; Vol. 283, No. 9. pp. 1145-1150.
@article{d1ac752ecd96476c8302fe402acdf973,
title = "Intravenous tissue-type plasminogen activator for treatment of acute stroke: The standard treatment with alteplase to reverse stroke (STARS) study",
abstract = "Context: Tissue-type plasminogen activator (tPA) is the only therapy for acute ischemic stroke approved by the Food and Drug Administration. Objective: To assess the safety profile and to document clinical outcomes and adverse events in patients treated with intravenous tPA for acute stroke in clinical practice. Design and Setting: Prospective, multicenter study of consecutive patients enrolled between February 1997 and December 1998 at 57 medical centers in the United States (24 academic and 33 community). Intervention: Intravenous tPA (recombinant alteplase). Patients: Three hundred eighty-nine patients with a mean age of 69 years (range, 28-100 years); 55{\%} were men. Main Outcome Measures: Time intervals between stroke symptom onset, hospital arrival, and treatment with tPA; pretreatment computed tomographic scan results, intracerebral hemorrhage, and major systemic bleeding. The modified Rankin Scale score was used to assess clinical outcomes at 30 days. Results: Median time from stroke onset to treatment was 2 hours 44 minutes, and the median baseline National Institutes of Health Stroke Scale score was 13. The 30-day mortality rate was 13{\%}. At 30 days after treatment, 35{\%} of patients had very favorable outcomes (modified Rankin score, 0-1) and 43{\%} were functionally independent (modified Rankin score, 0-2). Thirteen patients (3.3{\%}) experienced symptomatic intracerebral hemorrhage, including 7 who died. Twenty-eight patients (8.2{\%}) had asymptomatic intracerebral hemorrhage within 3 days of treatment with tPA. Protocol violations were reported for 127 patients (32.6{\%}), and included treatment with tPA more than 3 hours after symptom onset in 13.4{\%}, treatment with anticoagulants within 24 hours of tPA administration in 9.3{\%}, and tPA administration despite systolic blood pressure exceeding 185 mm Hg in 6.7{\%}. A multivariate analysis found predictors of favorable outcome to be a less severe baseline National Institutes of Health Stroke Scale score, absence of specific abnormalities (effacement or hypodensity of >33{\%} of the middle cerebral artery territory or a hyperdense middle cerebral artery) on the baseline computed tomographic scan, an age of 85 years or younger, and a lower mean arterial pressure at baseline. Conclusions: This study, conducted at multiple institutions throughout the United States, suggests that favorable clinical outcomes and low rates of symptomatic intracerebral hemorrhage can be achieved using tPA for stroke treatment.",
author = "Albers, {Gregory W.} and Bates, {Vernice E.} and Wayne Clark and Rodney Bell and Piero Verro and Hamilton, {Scott A.}",
year = "2000",
month = "3",
day = "1",
language = "English (US)",
volume = "283",
pages = "1145--1150",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Intravenous tissue-type plasminogen activator for treatment of acute stroke

T2 - The standard treatment with alteplase to reverse stroke (STARS) study

AU - Albers, Gregory W.

AU - Bates, Vernice E.

AU - Clark, Wayne

AU - Bell, Rodney

AU - Verro, Piero

AU - Hamilton, Scott A.

PY - 2000/3/1

Y1 - 2000/3/1

N2 - Context: Tissue-type plasminogen activator (tPA) is the only therapy for acute ischemic stroke approved by the Food and Drug Administration. Objective: To assess the safety profile and to document clinical outcomes and adverse events in patients treated with intravenous tPA for acute stroke in clinical practice. Design and Setting: Prospective, multicenter study of consecutive patients enrolled between February 1997 and December 1998 at 57 medical centers in the United States (24 academic and 33 community). Intervention: Intravenous tPA (recombinant alteplase). Patients: Three hundred eighty-nine patients with a mean age of 69 years (range, 28-100 years); 55% were men. Main Outcome Measures: Time intervals between stroke symptom onset, hospital arrival, and treatment with tPA; pretreatment computed tomographic scan results, intracerebral hemorrhage, and major systemic bleeding. The modified Rankin Scale score was used to assess clinical outcomes at 30 days. Results: Median time from stroke onset to treatment was 2 hours 44 minutes, and the median baseline National Institutes of Health Stroke Scale score was 13. The 30-day mortality rate was 13%. At 30 days after treatment, 35% of patients had very favorable outcomes (modified Rankin score, 0-1) and 43% were functionally independent (modified Rankin score, 0-2). Thirteen patients (3.3%) experienced symptomatic intracerebral hemorrhage, including 7 who died. Twenty-eight patients (8.2%) had asymptomatic intracerebral hemorrhage within 3 days of treatment with tPA. Protocol violations were reported for 127 patients (32.6%), and included treatment with tPA more than 3 hours after symptom onset in 13.4%, treatment with anticoagulants within 24 hours of tPA administration in 9.3%, and tPA administration despite systolic blood pressure exceeding 185 mm Hg in 6.7%. A multivariate analysis found predictors of favorable outcome to be a less severe baseline National Institutes of Health Stroke Scale score, absence of specific abnormalities (effacement or hypodensity of >33% of the middle cerebral artery territory or a hyperdense middle cerebral artery) on the baseline computed tomographic scan, an age of 85 years or younger, and a lower mean arterial pressure at baseline. Conclusions: This study, conducted at multiple institutions throughout the United States, suggests that favorable clinical outcomes and low rates of symptomatic intracerebral hemorrhage can be achieved using tPA for stroke treatment.

AB - Context: Tissue-type plasminogen activator (tPA) is the only therapy for acute ischemic stroke approved by the Food and Drug Administration. Objective: To assess the safety profile and to document clinical outcomes and adverse events in patients treated with intravenous tPA for acute stroke in clinical practice. Design and Setting: Prospective, multicenter study of consecutive patients enrolled between February 1997 and December 1998 at 57 medical centers in the United States (24 academic and 33 community). Intervention: Intravenous tPA (recombinant alteplase). Patients: Three hundred eighty-nine patients with a mean age of 69 years (range, 28-100 years); 55% were men. Main Outcome Measures: Time intervals between stroke symptom onset, hospital arrival, and treatment with tPA; pretreatment computed tomographic scan results, intracerebral hemorrhage, and major systemic bleeding. The modified Rankin Scale score was used to assess clinical outcomes at 30 days. Results: Median time from stroke onset to treatment was 2 hours 44 minutes, and the median baseline National Institutes of Health Stroke Scale score was 13. The 30-day mortality rate was 13%. At 30 days after treatment, 35% of patients had very favorable outcomes (modified Rankin score, 0-1) and 43% were functionally independent (modified Rankin score, 0-2). Thirteen patients (3.3%) experienced symptomatic intracerebral hemorrhage, including 7 who died. Twenty-eight patients (8.2%) had asymptomatic intracerebral hemorrhage within 3 days of treatment with tPA. Protocol violations were reported for 127 patients (32.6%), and included treatment with tPA more than 3 hours after symptom onset in 13.4%, treatment with anticoagulants within 24 hours of tPA administration in 9.3%, and tPA administration despite systolic blood pressure exceeding 185 mm Hg in 6.7%. A multivariate analysis found predictors of favorable outcome to be a less severe baseline National Institutes of Health Stroke Scale score, absence of specific abnormalities (effacement or hypodensity of >33% of the middle cerebral artery territory or a hyperdense middle cerebral artery) on the baseline computed tomographic scan, an age of 85 years or younger, and a lower mean arterial pressure at baseline. Conclusions: This study, conducted at multiple institutions throughout the United States, suggests that favorable clinical outcomes and low rates of symptomatic intracerebral hemorrhage can be achieved using tPA for stroke treatment.

UR - http://www.scopus.com/inward/record.url?scp=0034161354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034161354&partnerID=8YFLogxK

M3 - Article

C2 - 10703776

AN - SCOPUS:0034161354

VL - 283

SP - 1145

EP - 1150

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 9

ER -